Current biosimilar anti-VEGF drugs in retinal diseases

Anti-vascular endothelial growth factor (anti-VEGF) drug is a biological drug that is widely used in the treatment of retinal diseases and imposes a high financial burden on the healthcare system. The introduction of biosimilar drugs has come to the forefront with the expiration of patents on biological drugs. Biosimilar drugs have the same effectiveness and safety, but are more cost-effective. This feature of biosimilar drugs offers an important opportunity to reduce healthcare costs and to ensure patient compliance. This review aims to provide an overview of biosimilar drugs, highlight their advantages, and discuss both approved and investigational anti-VEGF biosimilar drugs. The goal was to provide ophthalmologists with a comprehensive understanding of this rapidly evolving field.